CXCR6 and melanoma: The specificity of reverse signaling was proven by silencing experiments, as well as by transfection experiments using a CXCL16-negative, CXCR6-negative melanoma cell line to investigate intracellular signaling and biological effects upon stimulation with CXCR6.